Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Jun;65(6):839-40.
doi: 10.1136/ard.2005.044685.

Eosinophilic cellulitis (Wells' syndrome) as a cutaneous reaction to the administration of adalimumab

P Boura, A Sarantopoulos, I Lefaki, P Skendros, P Papadopoulos
Review

Eosinophilic cellulitis (Wells' syndrome) as a cutaneous reaction to the administration of adalimumab

P Boura et al. Ann Rheum Dis. 2006 Jun.
No abstract available

PubMed Disclaimer

References

    1. Holme S A, McHenry P. Nodular presentation of eosinophilic cellulitis (Wells' syndrome). Clin Exp Dermatol 200126677–679. - PubMed
    1. French L E, Shapiro M, Junkins‐Hopkins J M, Wolfe J T, Rook A H. Eosinophilic fasciitis and eosinophilic cellulitis in a patient with abnormal circulating clonal T cells: increased production of interleukin 5 and inhibition by interferon alfa. J Am Acad Dermatol 2003491170–1174. - PubMed
    1. Seckin D, Demirhan B. Drugs and Well's syndrome: a possible casual relationship? Int J Dermatol 200140138–140. - PubMed
    1. Beuthien W, Mellinghoff H U, von Kempis J. Skin reaction to adalimumab. Arthritis Rheum 2004501690–1692. - PubMed
    1. Scheinfeld N. Adalimumab: a review of side effects. Expert Opin Drug Saf 20054637–641. - PubMed

MeSH terms